Nobuhiro Shibata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nobuhiro Shibata has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Shogen Boku
Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan
9 shared publications - Daisuke Hashimoto
Department of Pancreatobiliary Surgery Kansai Medical University Osaka Japan
5 shared publications - Sohei Satoi
Department of Pancreatobiliary Surgery, Kansai Medical University, Hirakata, Japan
5 shared publications - Tatsuki Ikoma
Department of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan
5 shared publications - Tsukasa Ikeura
Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan
5 shared publications - Toshihiko Matsumoto
Department of Medical Oncology, Ichinoimiya Nishi Hospital, Ichinomiya City, Japan
4 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 1-14
Early-onset DAT-negative autoimmune hemolytic anemia induced by pembrolizumab in perioperative triple-negative breast cancer: a case report
Introduction: Hematological immune-related adverse events associated with immune checkpoint inhibitors (ICIs) are rare, and autoimmune hemolytic anemia (AIHA) is particularly uncommon. Case Presentation: A 71-year-old woman with stage IIA triple-negative breast cancer received perioperative pembrolizumab with carboplatin and paclitaxel. During the first treatment cycle, she developed acute severe anemia with laboratory findings consistent with hemolysis. Despite a negative direct antiglobulin test (DAT), major alternative causes of hemolysis were considered unlikely, leading to a clinical diagnosis of suspected ICI-associated AIHA. Oral prednisolone (1 mg/kg) promptly resolved hemolysis without recurrence. Pembrolizumab was discontinued; however, imaging demonstrated a clinical complete response, and subsequent surgery confirmed a pathological complete response (pCR). Conclusion: This case demonstrates that AIHA during ICI therapy may occur despite a negative DAT and underscores the importance of prompt recognition and corticosteroid therapy. Favorable oncologic outcomes, including pCR, may still be achieved despite early discontinuation of ICI therapy.
- 22 June 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 1-14
Open AccessEarly-onset DAT-negative autoimmune hemolytic anemia induced by pembrolizumab in perioperative triple-negative breast cancer: a case report
Introduction: Hematological immune-related adverse events associated with immune checkpoint inhibitors (ICIs) are rare, and autoimmune hemolytic anemia (AIHA) is particularly uncommon. Case Presentation: A 71-year-old woman with stage IIA triple-negative breast cancer received perioperative pembrolizumab with carboplatin and paclitaxel. During the first treatment cycle, she developed acute severe anemia with laboratory findings consistent with hemolysis. Despite a negative direct antiglobulin test (DAT), major alternative causes of hemolysis were considered unlikely, leading to a clinical diagnosis of suspected ICI-associated AIHA. Oral prednisolone (1 mg/kg) promptly resolved hemolysis without recurrence. Pembrolizumab was discontinued; however, imaging demonstrated a clinical complete response, and subsequent surgery confirmed a pathological complete response (pCR). Conclusion: This case demonstrates that AIHA during ICI therapy may occur despite a negative DAT and underscores the importance of prompt recognition and corticosteroid therapy. Favorable oncologic outcomes, including pCR, may still be achieved despite early discontinuation of ICI therapy.
- Open Access
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
Introduction Addition of bevacizumab and paclitaxel as induction therapy prior to standard atezolizumab and nab-paclitaxel in patients with programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) may help to overcome vascular endothelial growth factor-associated resistance mechanisms that limit the immune-mediated antitumour efficacy of atezolizumab and nab-paclitaxel. Methods and analysis The Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+TNBC (INDUCE) study is a multicentre, randomised, open-label, phase II trial designed to evaluate the efficacy and safety of two cycles of induction therapy with bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel compared with standard atezolizumab and nab-paclitaxel in patients with PD-L1-positive mTNBC. The primary outcome of the study is progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumours, V.1.1. We have estimated that 89 PFS events are needed to allow a power of 80% to detect a difference between treatment groups at a one-sided significance level of 10% in this study. The target sample size is set to 106 patients to account for dropouts. Ethics and dissemination The study protocol and informed consent form have been approved by the Certified Research Review Board at the Nagoya University Graduate School of Medicine, Nagoya, Japan. Study results will be presented at international conferences and published in a peer-reviewed journal. Trial registration number jRCTs041240039 NCT06793553.
Open AccessRandomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
Introduction Addition of bevacizumab and paclitaxel as induction therapy prior to standard atezolizumab and nab-paclitaxel in patients with programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) may help to overcome vascular endothelial growth factor-associated resistance mechanisms that limit the immune-mediated antitumour efficacy of atezolizumab and nab-paclitaxel. Methods and analysis The Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+TNBC (INDUCE) study is a multicentre, randomised, open-label, phase II trial designed to evaluate the efficacy and safety of two cycles of induction therapy with bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel compared with standard atezolizumab and nab-paclitaxel in patients with PD-L1-positive mTNBC. The primary outcome of the study is progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumours, V.1.1. We have estimated that 89 PFS events are needed to allow a power of 80% to detect a difference between treatment groups at a one-sided significance level of 10% in this study. The target sample size is set to 106 patients to account for dropouts. Ethics and dissemination The study protocol and informed consent form have been approved by the Certified Research Review Board at the Nagoya University Graduate School of Medicine, Nagoya, Japan. Study results will be presented at international conferences and published in a peer-reviewed journal. Trial registration number jRCTs041240039 NCT06793553.
- Open Access
- 6 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study
This study examined the feasibility of a steroid-sparing approach in a dose-dense AC regimen in breast cancer patients, while integrating olanzapine to man
- 6 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessEfficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study
This study examined the feasibility of a steroid-sparing approach in a dose-dense AC regimen in breast cancer patients, while integrating olanzapine to man
- Open Access
- 15 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab
Purpose: The combination of lenvatinib plus pembrolizumab (LP) is a standard treatment for advanced or recurrent endometrial cancer. However, the optimal starting dose of lenvatinib is debated due to its toxicity profile. This study aimed to evaluate the effectiveness and safety of the LP regimen in a real-world setting and to investigate the impact of the lenvatinib starting dose on survival outcomes. Methods: We conducted a retrospective analysis of 33 patients with advanced or recurrent endometrial cancer treated with the LP regimen at Kansai Medical University Hospital between February 2022 and August 2025. We evaluated the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Prognostic factors for survival were identified using the Kaplan-Meier method and Cox proportional hazards models. Results: The median follow-up was 27.6 months. The ORR was 48.5%, with a median PFS of 6.7 months and a median OS of 21.7 months. In exploratory multivariable analysis adjusting for age ≥ 75 years and ECOG PS ≥ 1 , a lenvatinib starting dose < 20 mg (vs. 20 mg) was associated with shorter PFS (aHR 5.83; 95% CI 1.84–18.43; p = 0.003). In contrast, peritoneal metastasis (present vs. absent) was independently associated with shorter OS (aHR 7.51; 95% CI 1.87–30.25; p = 0.005). Conclusion: In this real-world cohort, LP therapy was effective and tolerable. In exploratory analyses, lenvatinib starting dose and peritoneal metastasis showed distinct associations with PFS and OS, respectively; however, non-random dose selection and baseline imbalances limit causal interpretation. These findings should be considered hypothesis-generating and warrant prospective validation, particularly for patients with peritoneal metastasis.
- 15 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessImpact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab
Purpose: The combination of lenvatinib plus pembrolizumab (LP) is a standard treatment for advanced or recurrent endometrial cancer. However, the optimal starting dose of lenvatinib is debated due to its toxicity profile. This study aimed to evaluate the effectiveness and safety of the LP regimen in a real-world setting and to investigate the impact of the lenvatinib starting dose on survival outcomes. Methods: We conducted a retrospective analysis of 33 patients with advanced or recurrent endometrial cancer treated with the LP regimen at Kansai Medical University Hospital between February 2022 and August 2025. We evaluated the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Prognostic factors for survival were identified using the Kaplan-Meier method and Cox proportional hazards models. Results: The median follow-up was 27.6 months. The ORR was 48.5%, with a median PFS of 6.7 months and a median OS of 21.7 months. In exploratory multivariable analysis adjusting for age ≥ 75 years and ECOG PS ≥ 1 , a lenvatinib starting dose < 20 mg (vs. 20 mg) was associated with shorter PFS (aHR 5.83; 95% CI 1.84–18.43; p = 0.003). In contrast, peritoneal metastasis (present vs. absent) was independently associated with shorter OS (aHR 7.51; 95% CI 1.87–30.25; p = 0.005). Conclusion: In this real-world cohort, LP therapy was effective and tolerable. In exploratory analyses, lenvatinib starting dose and peritoneal metastasis showed distinct associations with PFS and OS, respectively; however, non-random dose selection and baseline imbalances limit causal interpretation. These findings should be considered hypothesis-generating and warrant prospective validation, particularly for patients with peritoneal metastasis.
- Open Access
- 22 November 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (12) , 1115
The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study
Purpose: We performed post-marketing surveillance of the safety and effectiveness of 3.6 mg pegfilgrastim to prevent chemotherapy-induced febrile neutropenia (FN) in real-world conditions in Japan. Methods: Patients were registered between June 2015 and May 2017 and followed prospectively. Pegfilgrastim was administered once every chemotherapy cycle (maximum 6 cycles). Use of pegfilgrastim, safety, and effectiveness in reducing FN were evaluated. Results: From 300 institutions, 1,597 patients were registered and 1,479 patients were analyzed. Pegfilgrastim was given as primary prophylaxis (750 patients), as secondary prophylaxis (727 patients), or for therapeutic purposes (2 patients). The most common primary diseases were breast cancer (51.4%) and non-Hodgkin lymphoma (25.6%). Adverse events (AEs) occurred in 36.4% of patients and adverse drug reactions (ADR) in 18.5%. Common ADRs included back pain (3.6%), pyrexia (3.1%), arthralgia (2.1%), hepatic function abnormal (1.5%), myalgia (1.4%), and bone pain (1.0%). All back and/or bone pain-related ADRs were non-serious and well-controlled with non-steroidal anti-inflammatory drugs. Docetaxel-cyclophosphamide therapy among breast cancer patients was a factor influencing bone and/or back pain-related AEs by multivariate logistic regression analysis (odds ratios vs. fluorouracil-epirubicin-cyclophosphamide therapy: 2.32, P = 0.031). FN was observed in 5.3% (primary prophylaxis) and 2.5% (secondary prophylaxis) of the effectiveness analysis set in cycle 1 and decreased with increasing cycles. Conclusion: This survey confirmed that both primary and secondary prophylaxis using pegfilgrastim reduced FN in the real-world setting. No new safety concerns were identified. This survey was retrospectively registered on 26 April 2024 in the University Hospital Medical Information Network Clinical Trial Registry (UMIN000054267).
- 22 November 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (12) , 1115
Open AccessThe safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study
Purpose: We performed post-marketing surveillance of the safety and effectiveness of 3.6 mg pegfilgrastim to prevent chemotherapy-induced febrile neutropenia (FN) in real-world conditions in Japan. Methods: Patients were registered between June 2015 and May 2017 and followed prospectively. Pegfilgrastim was administered once every chemotherapy cycle (maximum 6 cycles). Use of pegfilgrastim, safety, and effectiveness in reducing FN were evaluated. Results: From 300 institutions, 1,597 patients were registered and 1,479 patients were analyzed. Pegfilgrastim was given as primary prophylaxis (750 patients), as secondary prophylaxis (727 patients), or for therapeutic purposes (2 patients). The most common primary diseases were breast cancer (51.4%) and non-Hodgkin lymphoma (25.6%). Adverse events (AEs) occurred in 36.4% of patients and adverse drug reactions (ADR) in 18.5%. Common ADRs included back pain (3.6%), pyrexia (3.1%), arthralgia (2.1%), hepatic function abnormal (1.5%), myalgia (1.4%), and bone pain (1.0%). All back and/or bone pain-related ADRs were non-serious and well-controlled with non-steroidal anti-inflammatory drugs. Docetaxel-cyclophosphamide therapy among breast cancer patients was a factor influencing bone and/or back pain-related AEs by multivariate logistic regression analysis (odds ratios vs. fluorouracil-epirubicin-cyclophosphamide therapy: 2.32, P = 0.031). FN was observed in 5.3% (primary prophylaxis) and 2.5% (secondary prophylaxis) of the effectiveness analysis set in cycle 1 and decreased with increasing cycles. Conclusion: This survey confirmed that both primary and secondary prophylaxis using pegfilgrastim reduced FN in the real-world setting. No new safety concerns were identified. This survey was retrospectively registered on 26 April 2024 in the University Hospital Medical Information Network Clinical Trial Registry (UMIN000054267).
- Open Access
- 10 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-9
Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck
Background Recent studies have suggested a correlation between ABO blood type and the effectiveness of immune checkpoint inhibitors. However, the relationship between ABO blood type and response to pembrolizumab monotherapy as first-line treatment for squamous cell carcinoma of the head and neck (SCCHN) remains unclear. Method We retrospectively analyzed the patients who were treated with pembrolizumab as the first-line treatment for locally advanced, recurrent, or metastatic SCCHN between May 2020 and September 2024. Result A total of 38 cases were analysed in this study. The ABO blood types of patients were as follows: 15 (39.5%) were type A, 9 (23.7%) were type B, 3 (7.9%) were type AB, and 11 (28.9%) were type O. Median Overall survival (OS) by blood type was 28.9 months for type A, 7.8 months for type B, 45.6 months for type O, and 21.4 months for type AB. The OS of B antigen-positive group (B group; B or AB) was significantly poorer than that of B antigen-negative group (non-B group; A or O) (7.8 months [95% CI, 3.0-16.4] vs. 28.9 months [95% CI, 10.7–45.6], p = 0.0022). Progression-free survival (PFS) was 2.6 (95% CI, 1.2–7.6) months vs. 7.2 (95% CI, 3.5–24.1) months (p = 0.06), overall response rate (ORR) was 25.0 vs. 46.2% (p = 0.29) and disease control rate (DCR) was 41.7 vs. 76.9% (p = 0.06), respectively. Conclusion In this cohort, the presence of B antigen provides a significant disadvantage in terms of survival in patients using pembrolizumab for SCCHN.
- 10 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-9
Open AccessRelationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck
Background Recent studies have suggested a correlation between ABO blood type and the effectiveness of immune checkpoint inhibitors. However, the relationship between ABO blood type and response to pembrolizumab monotherapy as first-line treatment for squamous cell carcinoma of the head and neck (SCCHN) remains unclear. Method We retrospectively analyzed the patients who were treated with pembrolizumab as the first-line treatment for locally advanced, recurrent, or metastatic SCCHN between May 2020 and September 2024. Result A total of 38 cases were analysed in this study. The ABO blood types of patients were as follows: 15 (39.5%) were type A, 9 (23.7%) were type B, 3 (7.9%) were type AB, and 11 (28.9%) were type O. Median Overall survival (OS) by blood type was 28.9 months for type A, 7.8 months for type B, 45.6 months for type O, and 21.4 months for type AB. The OS of B antigen-positive group (B group; B or AB) was significantly poorer than that of B antigen-negative group (non-B group; A or O) (7.8 months [95% CI, 3.0-16.4] vs. 28.9 months [95% CI, 10.7–45.6], p = 0.0022). Progression-free survival (PFS) was 2.6 (95% CI, 1.2–7.6) months vs. 7.2 (95% CI, 3.5–24.1) months (p = 0.06), overall response rate (ORR) was 25.0 vs. 46.2% (p = 0.29) and disease control rate (DCR) was 41.7 vs. 76.9% (p = 0.06), respectively. Conclusion In this cohort, the presence of B antigen provides a significant disadvantage in terms of survival in patients using pembrolizumab for SCCHN.
- Open Access
- 23 June 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (5) , 1157-1158
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer
- 23 June 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (5) , 1157-1158
Open AccessCorrection: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer
- Open Access
- 20 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 841-856
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer
Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is a current standard first-/second-line treatment for hormone receptor (HR)-positive, HER2-negative advanced/metastatic breast cancer (AMBC). We aimed to provide real-world evidence regarding CDK4/6i therapy in this population. Methods: In this multicenter observational study, data from patients who had started CDK4/6i therapy between January 1, 2019, and December 31, 2021, as first-/second-line treatment for AMBC were used; real-world progression-free survival (rwPFS), chemotherapy-free survival, and overall survival were analyzed using the Kaplan–Meier method. Additionally, data were analyzed by separating patients with treatment-free interval (TFI) < 12 months (deemed resistant to ET) from the first-line treatment group (hereafter, the exclusive first-line treatment group). Results: Data from 745 patients were analyzed. Compared with palbociclib, abemaciclib was used in younger patients and those with expected poor prognosis. Median rwPFS was 36.8, 17.8, and 31.4 months in patients with de novo stage IV disease, TFI < 12 months, and TFI ≥ 12 months, respectively, in the first-line treatment group, and 17.4 months in the second-line treatment group. In the exclusive first-line treatment group, median rwPFS of the subsequent treatment after initial CDK4/6i plus ET was < 7 months, regardless of the type of subsequent treatment; prognosis was especially poor in those who were switched to chemotherapy. Conclusions: The real-world survival outcomes found in this study for patients receiving first-/second-line CDK4/6i therapy were consistent with those of randomized phase 3 studies. As outcomes of subsequent treatment after initial CDK4/6i plus ET remain insufficient, further improvement in treatment is necessary.
- 20 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 841-856
Open AccessReal-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer
Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is a current standard first-/second-line treatment for hormone receptor (HR)-positive, HER2-negative advanced/metastatic breast cancer (AMBC). We aimed to provide real-world evidence regarding CDK4/6i therapy in this population. Methods: In this multicenter observational study, data from patients who had started CDK4/6i therapy between January 1, 2019, and December 31, 2021, as first-/second-line treatment for AMBC were used; real-world progression-free survival (rwPFS), chemotherapy-free survival, and overall survival were analyzed using the Kaplan–Meier method. Additionally, data were analyzed by separating patients with treatment-free interval (TFI) < 12 months (deemed resistant to ET) from the first-line treatment group (hereafter, the exclusive first-line treatment group). Results: Data from 745 patients were analyzed. Compared with palbociclib, abemaciclib was used in younger patients and those with expected poor prognosis. Median rwPFS was 36.8, 17.8, and 31.4 months in patients with de novo stage IV disease, TFI < 12 months, and TFI ≥ 12 months, respectively, in the first-line treatment group, and 17.4 months in the second-line treatment group. In the exclusive first-line treatment group, median rwPFS of the subsequent treatment after initial CDK4/6i plus ET was < 7 months, regardless of the type of subsequent treatment; prognosis was especially poor in those who were switched to chemotherapy. Conclusions: The real-world survival outcomes found in this study for patients receiving first-/second-line CDK4/6i therapy were consistent with those of randomized phase 3 studies. As outcomes of subsequent treatment after initial CDK4/6i plus ET remain insufficient, further improvement in treatment is necessary.
- Open Access
- 19 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 857-866
Real-world evidence of febrile neutropenia-related hospitalization on patients with perioperative chemotherapy for early breast cancer in Japan
Purpose: To clarify particularly how febrile neutropenia-related hospitalization (FNH) affects patients’ daily lives, by analyzing real-world data on FNH among patients with early breast cancer (EBC) receiving perioperative chemotherapy in Japan. Methods: This retrospective nationwide large-scale database study was conducted using anonymized claims data from 2010 to 2020. The patients with EBC who had available surgical records were included. Men, those aged < 18 years, and those who had not available chemotherapy records were excluded. FNH was defined as hospitalization during perioperative chemotherapy for EBC, with administration of intravenous antibacterial drugs and a diagnosis of FN, sepsis, infection, or fever. Results: The analysis population included 33,310 EBC patients with a mean age of 56.9 years, who received a total of 267,535 perioperative chemotherapy cycles. FNH occurred in 1,910 patients (5.73%) and 2144 chemotherapy cycles (0.80%). Median duration of FNH was 6.0 days. Fourth-generation cephalosporins were the most used intravenous antibacterial drugs (50.42%). Median duration of intravenous antibacterial drugs administration was 4.0 days. Therapeutic granulocyte-colony stimulating factor (G-CSF) was used in 1285 patients (67.28%). Median cost for FNH was estimated to be 189 thousand yen in 1,474 chemotherapy cycles with FNH, in which patients received intravenous antibacterial drugs administration for 3–8 days. Conclusion: This nationwide real-world data analysis revealed the incidence, duration, treatment patterns, and medical cost of FNH in patients with EBC receiving perioperative chemotherapy in Japan. These findings indicate that FNH imposes a considerable burden on patients’ daily lives, including time and financial impacts, contributing to the implementation of appropriate shared decision-making for primary G-CSF prophylaxis.
- 19 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 857-866
Open AccessReal-world evidence of febrile neutropenia-related hospitalization on patients with perioperative chemotherapy for early breast cancer in Japan
Purpose: To clarify particularly how febrile neutropenia-related hospitalization (FNH) affects patients’ daily lives, by analyzing real-world data on FNH among patients with early breast cancer (EBC) receiving perioperative chemotherapy in Japan. Methods: This retrospective nationwide large-scale database study was conducted using anonymized claims data from 2010 to 2020. The patients with EBC who had available surgical records were included. Men, those aged < 18 years, and those who had not available chemotherapy records were excluded. FNH was defined as hospitalization during perioperative chemotherapy for EBC, with administration of intravenous antibacterial drugs and a diagnosis of FN, sepsis, infection, or fever. Results: The analysis population included 33,310 EBC patients with a mean age of 56.9 years, who received a total of 267,535 perioperative chemotherapy cycles. FNH occurred in 1,910 patients (5.73%) and 2144 chemotherapy cycles (0.80%). Median duration of FNH was 6.0 days. Fourth-generation cephalosporins were the most used intravenous antibacterial drugs (50.42%). Median duration of intravenous antibacterial drugs administration was 4.0 days. Therapeutic granulocyte-colony stimulating factor (G-CSF) was used in 1285 patients (67.28%). Median cost for FNH was estimated to be 189 thousand yen in 1,474 chemotherapy cycles with FNH, in which patients received intravenous antibacterial drugs administration for 3–8 days. Conclusion: This nationwide real-world data analysis revealed the incidence, duration, treatment patterns, and medical cost of FNH in patients with EBC receiving perioperative chemotherapy in Japan. These findings indicate that FNH imposes a considerable burden on patients’ daily lives, including time and financial impacts, contributing to the implementation of appropriate shared decision-making for primary G-CSF prophylaxis.
- 7 June 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (5) , 787-795
Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal adenocarcinoma
- 7 June 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (5) , 787-795
Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal adenocarcinoma